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Abstract.  Transforming growth factor-/3 (TGF-~) is a 
potent mediator of cell proliferation and extracellular 
matrix formation, depending on the cell type and the 
physiological conditions. TGF-~ is usually secreted in 
a "latent" complex that needs activation before it can 
exert its effects. Several observations correlate increased 
expression of TGF-/31 with tumorigenesis. To evaluate 
the physiological relevance of increased TGF-/31 syn- 
thesis in tumor cells we established cell clones over- 
expressing TGF-/~I  and observed the resulting physio- 
logical changes in TGF-~ overproducing cells in vitro 
and in vivo. As a model system we used the human 
E1A-transformed 293 tumor cells, which are insensi- 
tive to the direct growth modulatory effects of TGF-/L 
The selection of this cell line allows an assessment of 
physiological alterations independent of TGF-/~ induced 
proliferative changes. 
The use of two TGF-/~  1 expression vectors contain- 
ing either the natural or a modified TGF-/~I  precursor 
cDNA permitted the establishment of separate 293 
cell lines overexpressing latent or active TGF-/L  Com- 
parison of the resulting changes in glycolytic rate, ad- 
hesiveness and integrin and plasminogen activator ex- 
pression established that, in vitro, both types of clones 
behaved similarly, indicating that expression of latent 
TGF-/$ induces autocrine changes in the tumor cells 
and thus suggesting that some level of cell-associated 
activation occurs. TGF-/3 overexpression resulted in an 
increased metabolic rate due to enhanced glycolysis, 
a property long associated with tumor cells. This in- 
creased glycolysis was not associated with altered pro- 
liferation. Cells overexpressing TGF-~ also displayed 
enhanced fibronectin mRNA and plasminogen activa- 
tor synthesis and increased adhesiveness in vitro. They 
showed enhanced survival when plated sparsely on 
plastic in the absence of serum, and attached more 
readily to laminin. In addition, synthesis of several ~/1 
integrins, in particular the oil//31, ot2/~l, and a3/~ll, 
all of which recognize laminin, were enhanced. Finally, 
cells overexpressing active TGF-/~, but not latent TGF- 
~, also showed increased tumorigenicity in nude mice. 
Thus, an increase in endogenous TGF-/3 synthesis con- 
fers several proliferation-independent phenotypic 
changes which may be of significance for the survival 
of the tumor cell inoculum or its subsequent growth, 
and for tumor formation and development. In the case 
of cells expressing active TGF-/3, the release of active 
TGF-/~ into the vicinity of the tumor cells may also 
result in a more hospitable environment for tumor 
growth. 
T 
HE transforming growth factor-~ (TGF-~y family of 
structurally related growth and differentiation factors 
has been reported to display diverse biological activ- 
ities in a wide range of experimental settings. The effects of 
"I'GF-~ differ considerably, depending on cell type and physi- 
ological conditions.  In vitro experiments have revealed that 
members of the "I'GF-/~ family are able to function as potent 
1. Abbreviation used in this paper: TGF-/~, transforming growth factor-/L 
regulators of cellular proliferation  and differentiation,  as 
well as immunosuppression. It is  therefore assumed that 
TGF-~ plays a crucial role in these different processes in 
vivo. In addition, TGF-# is known to modulate the expres- 
sion of various proteins that contribute to extracellular ma- 
trix formation and to cell-matrix interaction.  Such altera- 
tions  are  expected to  exert  some  effects  on  phenotypic 
parameters of the ceils, such as increased extracellular ma- 
trix deposition  and cellular adhesiveness.  Many cell types 
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/3, each encoded by genes with a distinctive complement of 
transcriptional and translational regulatory elements. Since 
most cells have functional TGF-/3 receptors, it is generally 
assumed that the biological activities of TGF-/3 are exerted 
in an autocrine or paracrine fashion (Roberts and Sporn, 
1990). 
TGF-/3 is a disulfide-linked homodimeric protein which is 
secreted as part of a complex consisting of two units of the 
large precursor segment of the TGF-/3 propolypeptide linked 
in a non-covalent association with the mature TGF-/3 dimer. 
This complex is "latent" in the sense that it does not bind to 
TGF-/3 receptors and therefore cannot exert any biological 
activities associated with TGF-/3. The release under physio- 
logical conditions of active TGF-/3 from the latent complex 
may be a finely regulated event in which specific proteases 
are involved (Sato et al., 1990).  Thus, localized proteolytic 
activation of the complex may be a critical determinant of  the 
local concentration of the active form of TGF-~. 
Several  observations  correlate  increased  expression  of 
TGF-/3 with tumorigenesis. Viral transformation of normal 
rat kidney cells or NIH-3T3 fibroblasts was associated with 
a greater than 40-fold increase in TGF-/3 secretion (Anzano 
et al.,  1985).  In addition, transformation of 10T1/2 fibro- 
blasts by radiation resulted in increased rates of TGF-/3 secre- 
tion, and rat tracheal epithelial cells transformed by carcino- 
gens  or  irradiation  contained  elevated  levels  of TGF-~I 
mRNA (Ferriola et al., 1989; Schwarz et al., 1990).  More- 
over, analysis of TGF-ffl mRNA levels in specimens of hu- 
man tumors of various histological types demonstrated in- 
creased levels of expression in comparison with adjacent 
normal tissues  (Derynck et al.,  1987).  Similarly, breast, 
hepatocellular, and renal cell carcinomas, as well as T-cell 
leukemia cells, displayed elevated levels of TGF-/31 mRNA 
compared with their non-malignant counterparts (Gomella 
et al., 1989; Ito et al., 1991; Niitsu et al., 1988; Travers et 
al.,  1988).  Furthermore, TGF-/3 has recently been impli- 
cated as playing a critical role in the development of tumors 
in Rous sarcoma virus-infected chickens following wound- 
ing (Sieweke et al., 1990). Finally, metastatic fibrosarcomas 
derived by transfection of fibroblasts with any of four on- 
cogenes were reported to release TGF-/~ in its active form at 
significantly  higher  levels  than  the  corresponding  non- 
transfected cells (Schwarz et al., 1990). Activated TGF-/3 has 
been detected in conditioned medium from several other tu- 
mor cell lines as well (Knabbe et al., 1987; Liu et al., 1988; 
Schwarz et al., 1990; Jennings et al., 1991; Constam et al., 
1992). 
These observations suggest that TGF-~ synthesized by the 
tumor  cells  themselves  may  facilitate tumorigenesis  and 
regulate tumor cell behavior. However, by their very nature, 
data obtained from such descriptive approaches are limited 
and correlative.  Studies comparing TGF-/3 expression by 
surgically obtained tissue specimens are unavoidably com- 
plicated by cellular heterogeneity. Similarly, the multitude of 
cellular and genetic changes that follow viral transformation 
or oncogene transfection make assessment of the particular 
importance of TGF-/3 expression impossible. 
We addressed these issues in designing this study to evalu- 
ate the importance of  endogenous 1GF-/3 synthesis for tumor 
cells by generating stable transfected tumor cell lines that 
produce elevated levels of TGF-/3. We specifically wanted to 
evaluate its importance for tumor cell behavior in the ab- 
sence of a direct contribution by TGF-/~ to cellular prolifera- 
tion, which might otherwise interfere with an evaluation of 
other  TGF-/3-mediated phenotypic changes,  e.g.,  altered 
matrix production. In addition, many tumor cell lines have 
lost their sensitivity to the antiproliferative effects of TGF-/3 
and it has been proposed that a  loss of the autocrine an- 
tiproliferative effects of TGF-/3 may be a necessary step for 
progression to malignancy (Wakefield and Sporn,  1990),  a 
possibility recently reinforced by the observation that carci- 
nomas, but not papillomas have lost their responsiveness to 
the direct effects of TGF-/3 on proliferation (Haddow et al., 
1991). We have therefore chosen the human embryonic kid- 
ney cell line 293, which has incorporated a functional E1A 
gene derived from adenovirus 5 (Graham et al., 1977). The 
formation of E1A protein complexes with the endogenous 
retinoblastoma gene product and/or several other nuclear 
proteins  renders  these  ceils  insensitive to the  TGF-/3-in- 
duced modulation of proliferation, thus suggesting an in- 
volvement of the retinoblastoma gene product in TGF-/3- 
induced growth inhibition (Pietenpol et al., 1990). From the 
parental 293 cells, we generated recombinant cell lines trans- 
fected with a TGF-/31 expression vector, that secreted high 
levels of either latent TGF-~ complex or biologically active 
TGF-#I. 
Using these cell lines, which had an unaltered prolifera- 
tion rate, we asked several questions. First, we determined 
whether overexpression of biologically inactive, latent TGF- 
/3 resulted in any autocrine effects at all and in this context 
compared the physiological consequences of increased ex- 
pression of latent versus active TGF-/3. Second, we evaluated 
the behavior of  these cell lines overexpressing latent or active 
TGF-/~, in vitro, focusing on the most striking changes in 
glycolysis and adhesiveness. Finally, we examined the effect 
of overexpression of TGF-/3 on tumor formation in vivo. 
Materials and Methods 
Expression Plasmids for Latent and Active TGF-~I 
The parent plasmid used for expression of the TGF-~I cDNA was pRK5 
(Graycar et al., 1989) (see Fig. 1). This plasmid incorporates a human cyto- 
megalovirus promoter which controls the transcription of  the cDNA and has 
a high efficiency of transcription in human 293 cells. The promoter is fol- 
lowed by a short intron containing an sp6 promoter which in turn is followed 
by a polylinker in which the cDNA will be incorporated. The polylinker 
site is followed by a sequence from the SV-40 late region containing the sig- 
nais for polyadenylation and transcriptional termination. 
Plasmid pRKS-/~E is a derivative of pRK5 in which the human TGF-/31 
cDNA encoding the unmodified wild type TGF-/31 precursor (Derynck et 
ai.,  1985)  is inserted (see Fig.  1). The TGF-~I cDNA was engineered to 
obtain a high level of translation. The modifications of the cDNA, intro- 
duced by site-directed mutagenesis of the single-stranded cDNA in recom- 
binant MI3 derivatives (Zoller and Smith, 1984) were as follows. One muta- 
tion centered around the initiator ATG and converted the original sequence 
(Derynck et ai., 1985) into TCTAGAAACAATG-CK2GCCC. This mutation 
resulted in the introduction of a  unique restriction site for XbaI closely 
preceding the start codon. The Xbal site was subsequently used for incor- 
porating the cDNA into pRK5, so that virtually nothing of the originai long 
5' untranslated sequence was retained in the expression vector. This muta- 
genesis also generated a sequence context for the initiator ATG which con- 
formed well to the consensus sequence for eukaryotic mRNAs (Kozak, 
1989).  The sequence surrounding the ATG, incorporating an A-residue at 
the -3 position and a G at +4, is predicted to result in a high efficiency 
of translation. The second mutation removed the 86 bp CG-rich sequence 
immediately following the stop codon. Finally, a HindllI recognition site 
was introduced to immediately follow the Pst I site downstream from the 
The Journal  of Cell Biology,  Volume 118, 1992  716 3' untranslated region (position 2740; Derynck et al.,  1985).  After these 
mutations were introduced, the eDNA was excised and introduced as an 
Xbal-HindIII fragment into the Xbal-HindRI-opened pRK5 plasmid. 
Plasmid pRK5-151EC2S2 was derived from pRK5-/~IE (Fig.  1). Again 
using site-directed  mutagenesis,  codons for the two cysteine residues at po- 
sitions 223 and 225 in the TGF-/31 precursor were replaced  by TCT and 
AGC codons for serine. As shown by Brunner et al. (1989), these mutations 
in the TGF-/51 precursor eDNA result in expression of TGF-/51 that is largely 
biologically  active and thus apparently  no longer in a latent complex. 
Generation of  Stable Tmnsfected Clones 
Subconfluent  293 cells were transfected with 30 ~g of pRK5, pRKS-/31E, 
and pRKS-/31EC2S2 plasmid DNA mixed with 1.5/~g pRSV-Neo plasmid 
DNA by the calcium phosphate co-precipitation method (Gorman el al., 
1983; Ausubel et al.,  1991). Cells were maintained in RPMI with 5-10% 
FBS, and during exposure to precipitated DNA, cultures were incubated in 
F12/DME medium with 5 % FBS. Media were supplemented with I00 U/m1 
penicillin and 100/zg/rnl streptomycin.  Cells were incubated with the DNA 
precipitate for 5 h and then exposed to 15% glycerol in PBS at room temper- 
ature for 90 s. Two days later, cells were split 1:20 and grown in the presence 
of G418 (600-800/~g/ml) until colonies formed. Colonies were expanded 
and RNA was prepared (Chomczynski and Sacchi,  1987) for subsequent 
Northern analysis to detect'rGF-/31 mRNA. The transfected clonal cell lines 
with the highest plasmid-derived TGF-/31 mRNA levels were selected for 
characterization. All selected colonies were tested for mycoplasma contam- 
ination and found to be negative. 
mRNA Analysis 
Northern analysis for the presence of specific mRNAs proceeded as follows: 
Total RNA was electrophoresed in 1% agarose,  5 % formaldehyde gels, fol- 
lowed by etectrotransfer to nylon membranes (C~nescreen)  and UV cross- 
linking.  Membranes were probed with eDNA fragments radiolaboled  by 
the random priming method (Bochringer Mannheim Biochemicals, Indi- 
anapolis, IN) according to the manufacturer's directions.  The TGF-/51 probe 
was the 1.9-kbp EcoRI-HindllI eDNA insert of plasmid pRK5-/31E. The 
fibronectin probe was  the  1.0-kbp ClaI-BamHI fragment from plasmid 
pFH23 (obtained from Dr.  Z. Werb, University of California, San Fran- 
cisco, CA). All hybridizations  were performed under high-stringency  con- 
ditions.  Unhybridized probe was removed by washing membranes with 0.1 
x  SSC, 0.2%  SDS at 600C. 
RNase protection analyses to detect and quantitate levels of TGF-/31, -/32, 
and -/33 mRNA were performed as previously  described (Arrick el al., 
1990). 
Quantitation of TG  F-I~ Secretion 
To prepare conditioned medium, cells were incubated for 24 h in serum-free 
FI2/DME medium supplemented with transferrin (13.5 gg/ml), BSA (300 
gg/ml), and Hepes  (10 raM, pH 7.2).  The conditioned medium was col- 
lected and assayed for TGF-~-induced inhibition  of proliferation of CCL64 
mink lung cells,  with and without acid activation, as previously described 
(Arrick et al., 1990; Meager,  1991). The monolayers were then trypsinized 
and counted in a Coulter counter to allow normalization of the levels of 
secreted TGF-B against cell number. 
Assay  for Lactate Production 
Cells harvested from routine cultures with detaching solution (125 mM 
NaC1, 5 mM KC1, 5 mM glucose,  1 mM EDTA, 50 mM Hepes,  pH Z4), 
were washed with serum-free medium, and replated in triplicate in serum- 
free medium at a density of 4  x  105tmi on laminin-coated 24-well plates 
at 1 ml per well and incubated overnight at 37"C.  Laminin-coated plates 
were used in order to obtain an adherent monolayer.  Medium was then 
replaced  with sodium phosphate-containing buffer supplemented with 20 
mM glucose.  After a  1-h incubation, lactate levels were measured as de- 
scribed (Resnick el al., 1986). In this assay, lactate-dependent reduction of 
nicotine adenine dinucleotide  in the presence of lactate dehydrogenase was 
quantitated by measurement of OD at 339 nm. Cell counts obtained after 
trypsinization of the monolayers were used to normalize lactate determina- 
tions. 
Cell Adherence on Defined Substrates 
We evaluated the adherence and morphology of control and transfected cells 
plated on plastic in the presence and absence of serum. Cell suspensions 
in serum-free DME medium were obtained as described above, and 5  x 
lif  t cells (or 5  x  103 cells in some experiments) in 1 mt were plated per 
well in 24-well plates in the presence and absence of serum. 
Experiments were also carded out on surfaces coated with iaminin (from 
Engelbreth-Holms-Swarm  tumor,  Collaborative  Research)  or  plasma 
fibronectin (Collaborative Research Inc., Lexington, MA) in the presence 
of serum-free medium containing 2 % of Nutridoma (Boehringer  Mannheim 
Biochemicals),  a  medium supplement that lacks the attachment factors 
present in serum. The wells were coated for 16 h at 40C with laminin or 
fibronectin at 10 and 5 ~g/ml, respectively.  Unoccupied sites on the sub- 
strates  were blocked with 0.2%  BSA in Ca  2+- and Mg2+-free PBS (CMf- 
PBS) for 1 h before plating cells (Hall el al.,  1990). Cells were plated in 
24-well plates at a density of 4  x  104 cells/ml.  Morphology was evaluated 
at 4 h and at 2 and 4 d. 
Detection of  lntegrins by lraraunoprecipitations 
Antibodies used to detect integrins were obtained as follows:  rat mAbs 
against the human integrin subunits ~1 (AIIB2), or5 (BIIG2:  Werb et al., 
1989; Hall et al., 1990), and a6 (J1B5; Damsky et al., 1992) were produced 
as described. Other antibodies were obtained as follows: mouse monoclonal 
anti-u2 (P1H5) and c~3 (P1B5) were gifts of Drs. E. Wayner (Fred Hutchin- 
son Cancer Center,  Seattle,  WA) and W. Carter (Fred Hutchinson Cancer 
Center) (Wayner and Carter  1987);  mouse monoclonal  anti-cd  (TS217; 
Hemler et al.,  1984) was purchased as ACT-T-SET from T-Cell Sciences, 
(Cambridge, MA); mouse anti-oN (LM142) was a gift of  Dr. David Cheresh 
(Scripps  Institute,  La Jolla,  CA) (Cheresh and Harper,  1987).  Uncon- 
jugated rabbit anti-mouse IgG was pumhased from Jackson Immunore- 
search Lab Inc.  (West Grove,  PA).  Protein A-conjugated egarose beads 
were purchased from Sigma Chemical Co.  (St.  Louis, MO). 
Cells were either metabolically labeled or surface labeled. For metabolic 
labeling,  cells were harvested using trypsin-EDTA,  plated at a density of 
2  x  10  ~ cells per T75 flask in DME medium with 10% FBS and radiola- 
beled for 24 h with 50 ~Ci/ml 3H-glucosamine.  The cells were then har- 
vested with 2 mM EDTA in CMf-PBS, washed in PBS containing Ca  2+ and 
Mg  2+, and lysed in 25 mM "Iris buffer, pH Z2, containing 150 mM NaCI, 
0.5%  NP-40, and 1 mM PMSE Alternatively,  cells were harvested with 
EDTA as  described and  surface-labeled  with t2sI-iodine  using the lac- 
toperoxidase/glucose  oxidase method. After being washed in PBS contain- 
ing 50 mM Na-iodide and again in Ca  2+- and Mg2+-containing PBS, these 
cells were lysed as described for metabolically labeled cells.  Lysntes were 
centrifuged at 12,000 g for 10 min. All procedures were carried out at 4~ 
The supernatant was precleared with Sepharose 4B beads, and aliquots con- 
taining equal protein amounts (determined using the Lowry method; Aus- 
ubel el al., 1991) were incubated for 2 h or overnight with one of the follow- 
ing subunit-specific  monoclonal anti-integrin antibodies:  AIIB2 (anti-t31), 
TS2/7  (anti-al), P1H5 (anti-ct2),  P1B5 (anti-c~3), BIIG2 (anti-cr  J1B5 
(anti-c~6), or LM142 (anti-oN). The antibodies were present in excess such 
that addition  of another aliquot  of primary antibody,  following  the first 
round of precipitation, did not bring down any additional  material. The 
samples  were next incubated with a  1:100 dilution of rabbit anti-rat or 
anti-mouse IgG for 1 h, and then with 100 IA packed protein A-agarose 
beads for 2 h. The beads with bound immune complexes  were washed se- 
quentially with  10 mM  Tris-acelate,  pH  8.0, 0.5  mM  Ca  2+,  and 0.5% 
NP-40  (TNC),  TNC  with 1 M  NaC1, TNC  with 0.1% SDS,  and again 
with TNC. The proteins bound to the washed beads were analyzed by SDS- 
polyacrylamide  electrophoresis in 7%  polyacrylamide  gels  under non- 
reducing conditions, followed by autoradiography. 
Detection of  Proteases by Substrate 
Gel Electrophoresis 
To detect expression of extracellular matrix-degrading metaUoproteinases 
and plasminogen activators,  cell extracts and conditioned media were ana- 
lyzed on 10 % polyacrylamide-SDS gels copolymerized with either 1 mg/ml 
gelatin (for the detection of metalloproteinases) or 13/~g/ml plasminogen 
and 1 mg/ml casein (for the detection of plasminogen activators) as de- 
scribed previously (Unemori and Werb, 1986; Fisher and Werb, 1991). Be- 
fore this analysis, the conditioned media were concentrated by dialysis using 
Centriprep concentrator tubes  with a  10-kD  exclusion filter  (Amicon, 
Beverly, MA). To determine whether the substratum influenced  protein- 
ase expression,  cells were plated on fibronectin- or laminin-cuated plates 
in serum-free,  Nutridoma-containing medium,  or on plastic in serum- 
containing medium as described above. 
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Invasion Assay 
Cells  were  harvested  and  6  x  104  cells  in  200  /41  of  serum-free, 
Nutridoma-containin  8  medium were added to the upper section of Costar 
Transwetl filter culture chambers partitioned by a Nucleopore filter (growth 
surface area:  0.28  cm2;  Costar, Cambridge,  MA) that had been coated 
with a thin layer of Matrigel (Collaborative Research Inc., Lexington, MA), 
the  reconstituted  basement  membrane-like  extract  of  the  EHS  tumor 
(Librach et al.,  1991). After 24 or 48 h, the cultures were fixed with 2% 
glutaraldehyde and processed for scanning electron microscopy by standard 
methods (Librach et al.,  1991).  Filters were mounted such that either the 
top or the underside of the filter could be viewed. The presence of ceils on 
the underside of the filter constituted evidence of invasive activity. 
Tumor Formation in Nude Mice 
Subcordiuent cultures were detached with detaching solution (125  mM 
NaCl, 5 mM KCI, 5 mM glucose, 1 mM EDTA, 50 mM Hepes pH 7.4). 
Cells were resuspended in FI2:DME medium at a density of 3  x  10~/ml 
and kept on ice until injection. Female nude mice between 4- and 6-wk old 
(Charles River) were injected subcutaneously with 0.2 ml of  the cell suspen- 
sion. Some mice were injected with cell suspensions at two different sites. 
After 4 wk, mice were killed by cervical dislocation and the sizes of the 
subcutaneous tumor masses were measured in three dimensions (x, y, and 
z). From animals with a palpable tumor mass, we removed the lung, liver, 
kidneys, spleen, femur, and tumor, fixed the tissues in 10% formalin, and 
evaluated the organs and tissues macroscopically and histologically for the 
appearance of metastases. The microscopical examination of histological 
sections of the tissues was done by a veterinary pathologist. The volumes 
of the tumors were calculated as 0.Sx the product of the measurements in 
three dimensions (Tomayko  and Reynolds, 1989). 
Results 
Characterization of the Parent 293 Cells 
In this study we evaluated the effects of TGF-/~ overexpres- 
sion in 293 cells, a transformed and tumorigenic human kid- 
ney fibroblast cell line with an incorporated, functional E1A 
gene from adenovirus 5 (Graham et al., 1977).  Analysis of 
the TGF-B expression pattern in the untransfected cells re- 
vealed that they synthesized only TGF-/Yl mRNA of the ex- 
pected size of 2.5 kb. No traces of TGF-/~2 or -/33 mRNA 
were detected by RNAse protection assay (data not shown). 
Measurements of the TGF-/~ levels using a TGF-~ bioassay 
indicated that 0.3-0.4 rig/106 cells was secreted per 24 h. 
The requirement for acid activation to detect the TGF-B indi- 
cated that most, if not all, of the TGF-B was secreted in a 
latent form. 
The presence of TGF-/~ receptors in the nontransfected 
293 cells was assayed using specific cross-linking of cell sur- 
face proteins in the presence of ~2q-TGF-B1 essentially as 
described by Frolik et al.  (1984).  Analysis of the cross- 
linking pattern revealed the presence of all three known spe- 
cies of  TGF-B cell surface receptors or binding proteins, i.e., 
the type 165-kD receptor, the type I185-kD receptor and the 
large type HI proteoglycan (data not shown). Thus, the pa- 
rental 293 cells synthesize and secrete low levels of TGF-~ 
and have TGF-B receptors, suggesting that changes in endog- 
enous TGF-/3 synthesis could affect their cellular physiology 
in an autocrine fashion. 
Generation of Stable Cell Lines Overexpressing  Latent 
or Active TGF-fl 
We constructed two mammalian expression plasmids  for 
TGF-fll from the parental expression vector pRK5 as de- 
pBR322  pUC118 
ori 
CMV  ￿9  ,~ 
promoter/l  ~4~J  early 
enhancer  i  ~JSV40 
Intron  '4  ~V40 
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Figure 1. Schematic diagram of the TGF-~I expression plasmids 
pRK5-/31E and pRK5-~IEC2S2. The cytomegalovirus promoter 
segment with the direction of transcription is shown as a heavy 
black arrow, and the segments derived from SV-40 are shown as 
shaded boxes. The two TGF-B1 eDNA transcription units, corre- 
sponding to either plasmid, are shown with their flanking restric- 
tion sites. SS, signal sequence. 
scribed in Materials and Methods and diagrammed in Fig. 
1. Plasmid pRK5-BIE incorporates a human "I'GF-fll cDNA 
(Derynck et al., 1985), the expression of which should yield 
an unmodified human TGF-01 precursor protein, and thus 
TGF-/3 in its latent or biologically inactive complex. The sec- 
ond plasmid, pRKS-fllEC2S2, is identical to pRK5-BIE ex- 
cept for the replacement of the codons for two cysteines at 
positions 223 and 225 in the TGF-ffl precursor with serine 
codons, a mutation that results in secretion of TGF-B largely 
in its biologically active form ~runner et ai.,  1989). 
Transfection of  the individual TGF-/31 expression plasmids 
along with the pRSV-Neo plasmid containing the neomycin- 
resistance transcription unit, followed  by selection for G418- 
resistant clones, resulted in the generation of stable trans- 
fected 293 cell clones. Northern hybridization indicated that 
several of the G418-resistant cell lines expressed elevated 
levels of TGF-/31 mRNA (Fig, 2), the size of which agreed 
with the size predicted from the design of the expression 
plasmids. Two clonal cell lines transfeeted with pRKS-~E 
(B6  and  B9)  and  two  transfected  with  plasmid  pRKS- 
/31EC2S2 (C15 and C19) were selected for further analysis. 
As controls, two G418-resistant clones cotransfected with 
the parent pRK5 lacking any cDNA sequence (R1 and R6) 
were characterized in parallel with the TGF-13-overexpress- 
ing cell lines.  RNase protection assays indicated that the 
neomycin-resistant  control clones expressed 2nGF-t31 mRNA 
at levels equivalent to untransfected 293 cells and that the 
TGF-/3-overexpressing  B6 and C19 clones had about  100- 
fold higher levels of TGF-/31 mRNA (not shown). 
We  measured  secretion of TGF-B  by the  selected 293 
clones by assaying the serum-free conditioned medium for 
TGF-B bioactivity in a cell growth inhibition assay (Table I). 
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encoding  TGF-B1 by  trans- 
fected cell clones, determined 
by  Northern  hybridization. 
Cells were transfected  with pa- 
rental  plasmid pRK5 lacking 
TGF-B  eDNA (R), with pRKS- 
B1E (B), or with pRK5-BIE 
C2S2 (C). Each lane contained  18 ~g total RNA prepared from 
transfected cell clones as indicated. Equivalent RNA loading and 
transfer was confirmed by subsequent probing with a glyceralde- 
hyde-6-phosphate dehydrogenase eDNA. The TGF-B1 mRNA ex- 
pressed from the transfected expression plasmid is about 2-kb long 
on the basis of migration in the gel. The low endogenous TGF-B1 
mRNA levels are not detectable using the short duration of auto- 
radiography of this experiment and are more easily assessed by 
RNAse protection assay. 
The assay was done with and without acid activation, which 
quantitatively converts latent TGF-/3 to its biologically active 
form. The control transfected clones, like the parental 293 
cells, secreted low levels of TGF-B in the latent form. In con- 
trast,  the transfected clones transfected with pRK5-B1E or 
pRK5-~EC2S2  secreted TGF-B levels  100  to  300  times 
higher than the control clones. Their relative TGF-B levels 
were in agreement with the relative TGF-BI mRNA levels. 
As expected, ,,,99% or more of the TGF-B secreted by the 
clones transfected with pRK5-B1E was in the latent form. We 
do not know whether the very low levels of active TGF-/~ in 
the conditioned medium of  these clones are a result of  techni- 
cal manipulations, temperature- or protease-induced activa- 
tion, or activation in the bioassay system. In contrast, 50% 
of the TGF-B released by the stable clones transfected with 
the  pRK5-B1EC2S2  plasmid,  with  its  mutated  precursor 
eDNA, was in a biologically active form. Remarkably, the 
total  TGF-B expression  from this  plasmid  was  generally 
much higher than with the same expression vector contain- 
ing the unmodified TGF-/~ precursor eDNA (Arrick, B., and 
R. Derynck, unpublished data). 
Analysis of the TGF-B receptors by cross-linking, using 
~25I-TGF-B as ligand, indicated that all clones had the three 
TGF-B receptor types at their cell surface. Some differences 
in receptor levels between the different clones were appar- 
ent, suggesting clonal heterogeneity (data not shown). 
Table L Secretion of TGF-[3 by Transfected 293 Cell Clones 
TGF-$ bioactivity 
(ng/106 cells) 
Percent active 
Cell done  Without acid  With acid  without acidification 
R1  ND  0.42  - 
R6  ND  0.41  - 
B6  0.49  95  0.5 
B9  0.60  55  1.1 
C 15  58  110  52 
C19  69  125  56 
Serum-free conditioned medium was collected af~er a 24-h incubation and as- 
sayed for TGF-~ bioactivity by inhibition of [3H]TdR uptake by mink lung 
cells CCL64 with and without prior acid activation.  TGF-/~ bioactivity in the 
conditioned medium  of the two control clones was not detectable (ND)  without 
acid  activation.  Values reported  are means from triplicate  determinations. 
Average coefficient of variance was 7.6%. 
Table II. Lactate Production by Transfected 293 
Cell Clones 
Cell clone  Lactate 
(mmol/lO  5  cells~h) 
R1  37.3 + 0.73 
R6  39.0 •  1.3 
B6  59.3 •  4.1 
B9  53.6 •  0.74 
C15  54.1 •  1.4 
C19  50.1 •  0.79 
Cells were  incubated  overnight  in laminin-coated  plates  under serum-free  con- 
ditions, followed  by a 1-h incubation  in a phosphate-  and glucose-containing 
buffer. Lactate  production  was determined  by quantitative  conversion  to pyru- 
rate by lactate  dehydrogenase,  with stoichiometric  formation  of NADH (Res- 
nick et al., 1986). Data  are normalized  to cell  number  and presented  as means 
5: SD for triplicate  determinations. 
Increased Glycolysis in TGF-fl Overexpressing Cells 
Increased aerobic glycolysis by tumors has been noted for 
over half a century. More recently it was shown that TGF-/5 
was  able to  stimulate  glycolysis in  normal  rat fibroblasts 
mitogenically stimulated by TGF-~ (Boerner et al.,  1985). 
During the course of our experiments, we noted a more pro- 
nounced acidification of the medium by several of the clones 
overexpressing TGF-B, even though, as expected, there were 
no differences in proliferation rate between the overexpress- 
ing clones and the control clones. We therefore assessed the 
glycolytic activity of our transfected clones by measuring 
lactate production. We found that the pRK5-~E- and pRK5- 
B1EC2S2-transfected clones demonstrated a greater rate of 
lactate production than the control clones (Table II). This in- 
crease in lactate production was about equal to that observed 
upon exposure of rat kidney fibroblasts to exogenous TGF-B 
(Boerner et al.,  1985). 
It is important to observe that there was no major differ- 
ence in lactate production between the pRK5-/~IE clones B6 
and B9, and the pRK5-/SqEC2S2  clones C15 and C19. Thus, 
at least in this respect, the clones producing latent TGF-B be- 
haved similarly to those secreting active TGF-~5. This sug- 
gests that the clones producing latent TGF-B have the ability 
to activate it and are responsive to it. 
Adhesive and Invasive Properties 
During cell culture propagation of the transfected cells, we 
noted that clones overexpressing TGF-~ required longer ex- 
posure to trypsin-EDTA than the control clones. To evaluate 
this further, we studied the adhesive properties of these cells 
to plastic, laminin, and fibronectin. 
In one set of  experiments we plated and incubated the cells 
(5  x  104/ml) in the presence or absence of serum in plastic 
culture wells. When cultured on plastic in serum-free condi- 
tions, the control clones proliferated as non-adherent clumps 
of cells.  In contrast, the TGF-B-overproducing clones 136, 
B9, C15,  and C19 adhered to the plastic,  spread out, and 
proliferated into a monolayer. Again, there were no apparent 
differences between clones overproducing latent or active 
TGF-/~  (Fig.  3).  However,  when  plated  in  serum-free 
medium at very low density (5  x  l(P/ml), only the C15 and 
C19 clones, which expressed active TOF-/$1 attached, sur- 
vived, and proliferated (as assessed by phase-contrast mi- 
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expressing TGF-/3 in serum-free medium. 
R6, B6, and C15 cells were plated on un- 
coated plates for 5 d before photomicrogra- 
phy. Ceils were photographed  at a 200)< 
magnification. 
croscopy and trypan blue exclusion; data not shown), indi- 
cating the importance of the increased adhesiveness for cell 
survival. In the presence of serum, we observed no differ- 
ences in adherence or morphology between the control clones 
and the TGF-B-overproducing clones. 
We also evaluated the adhesive behavior of  the R6, B6, and 
C15 clones on laminin and fibronectin in serum-free medium 
containing  Nutridoma,  a  commercially available  additive 
that facilitates cell growth under serum-free conditions but 
lacks the attachment factors present in serum. When plated 
on fibronectin under these conditions, all clones tested at- 
tached  well  and  displayed  similar  morphology (Fig.  4). 
However, there were differences when the cells were seeded 
on laminin-coated plates. The R6 control cells formed cell 
clumps that did not attach during the first 4 h of culture. At 
2 D, the clumps of R6 cells were still only loosely attached. 
By four days the clumps were more firmly attached, but the 
cells had not spread (Fig,  4).  This inability to attach and 
spread on laminin was reminiscent of what occurred when 
these cells were plated on plastic in serum-free medium. In 
contrast,  the B6  and  C15  clones  readily attached  to  the 
laminin-coated plates in the presence of Nutridoma (Fig. 4). 
At early time points, the B6 line was able to spread more ex- 
tensively on laminin than the C15 line (Fig. 4), although nei- 
ther cell line spread as extensively on laminin as they did on 
fibronectin. Both cell lines proliferated under these condi- 
tions. 
Finally,  we evaluated the  invasiveness of several trans- 
fected clones using an in vitro invasion assay (Librach et al., 
1991).  Cells were seeded on Nucleopore filters coated with 
a thin layer of Matrigel, a commercially available basement 
membrane preparation.  The ability of the cells to invade 
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overexpressing cell clones in Nu- 
tridoma-containing medium. R6, 
B6,  and  C15  cells,  cultured  in 
DME medium containing Nutri- 
doma, were plated on fibronectin 
(Fn)- or laminin (Ln)-coated cul- 
ture wells. All three lines adhered 
and spread on fibronectin. Note 
that control R6 cells did not at- 
tach efficiently  to laminin and did 
not spread. In contrast,  TGF-~- 
overexpressing B6 and C15 cells 
attached  readily to laminin and 
spread  more  efficiently. Cells 
were  photographed  at  a  50x 
magnification. 
through the Matrigel and through the pores of the filters over 
a 48-h period was evaluated by scanning electron microscopy 
of both sides of each filter (data not shown). No evidence of 
invasion was detected for the R6 and C15 lines in three sepa- 
rate assays. A very low level of invasion by the B6 line was 
sometimes detected, but this was far less than that displayed 
by several other cell types tested  (Demeure et al.,  1991; 
Librach et al.,  1991; Walter, P., and C. H. Damsky, unpub- 
lished experiments. 
Expression of ~'bronectin,  lntegrins, and Proteinases 
Exogenous TGF-/3 has previously been shown to induce in- 
creased expression of the 9.1-kb fibronectin mRNA in human 
fibroblasts (Ignotz et al.,  1987;  Ishikawa et al.,  1990). We 
therefore determined the effects of the endogenous TGF-/~ 
overexpression on the expression of fibronectin mRNA. The 
three transfected clones with the highest TGF-~ expression 
levels, B6,  C15,  and C19,  had a  greatly increased level of 
fibronectin mRNA  in comparison with the control clones 
(Fig.  5).  Clone B9 displayed only a  moderate increase of 
fibronectin mRNA, consistent with an intermediate TGF-/3 
expression  level.  These  data  may  suggest  that  a  certain 
Figure 5. Expression of fibro- 
nectin mRNA by transfected 
cell  clones,  determined  by 
Northern hybridization. Each 
lane contained 18 #g of total 
RNA prepare from transfected 
293 cell clones as indicated. 
Estimated  from  the  migra- 
tion in the gel, the fibronectin mRNA is about 9-kb long. Equivalent 
RNA loading and transfer was confirmed by subsequent probing 
with a glyceraldehyde-6-phosphate dehydrogenase cDNA. 
threshold of  endogenous TGF-~ level must be reached before 
fibronectin gene expression is stimulated. 
The control and  TGF-~-overexpressing cells were also 
evaluated for changes in their levels of expression of several 
members of the integrin superfamily of extracellular matrix 
receptors (reviewed in Albeda and Buck,  1989). Cells that 
had been either metabolically or surface labeled were lysed 
and immunoprecipitated with subunit-specific mAbs and the 
results were similar for both labeling protocols. Experiments 
were carried out under conditions of antibody excess so that 
all antigen was precipitated in a single round of immunopre- 
cipitation, enabling levels of individual integrins present in 
each clone to be compared. All clones examined expressed 
all of the tested integrins at some level (or, or2, o~3, or5, ol6, 
/~1,  oN).  However,  the  B6,  C15,  and  C19  lines  showed 
elevated/~1  integrin levels in comparison with the control R6 
clone. Detailed analysis of the R6, B6, and C15 lines (Fig. 
6) showed that levels of c~2/~1 (a collagen and laminin recep- 
tor) and o~3//31 (a fibronectin, laminin, and collagen recep- 
tor) were particularly strongly affected. 
To determine whether increased TGF-~ expression influ- 
enced proteinase production by 293 cells, we analyzed the 
metalloproteinase and plasminogen activator levels in condi- 
tioned medium and cell extracts of the control R6 and TGF- 
/3-overexpressing  clones  B6  and  C15.  Experiments  were 
carried  out  using  cells  plated  in  Nutridoma-containing 
serum-free medium on plastic or laminin- or fibronectin- 
coated wells. This was done to determine whether substrate 
affected protease  expression.  A  gelatin-degrading  metal- 
loproteinase with an apparent molecular mass of 68 kD was 
present at similar low levels in the extracts and media of all 
three clones (not shown). All three clones also produced a 
casein/plasminogen-degrading  activity  with  the  apparent 
molecular mass ofpro-urokinase type plasminogen activator 
(52 kD) (Fig. 7). The C15 and the B6 cells, whether cultured 
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dium of  the transfected cell clones by plasminogen/casein substrate 
gel zymography. Cell clones R6, B6, and C15 were plated on plastic, 
fibronectin, or laminin. The prominent lysis zone in each well mi- 
grates with the mobility of  single chain urokinase-type plasminogen 
activator at 52 kD. The C15 and B6 line produced increased levels 
of this proteinase. There was no evidence of activated two chain 
urokinase. The gel was a 10% polyacrylamide gel. 
Figure 6. Expression of integrins by the TGF-/%overexpressing  cell 
clones. R6, B6, and C15 were metabolically labeled with 3H-glu- 
cosarnine for 24 h, extracted, and immunoprecipitated with mAbs 
specific for members of  the/31 integrin family as described in Mate- 
rials and Methods. Precipitates were analyzed by SDS-PAGE  under 
nonreducing conditions in 7.5% polyaerylamide gels. When com- 
pared to the R6 line, the B6 line displayed some elevation of all in- 
tegrin levels. The C15 line showed the greatest elevation in the level 
of the ~5/~1  fibronectin receptor. Similar results were obtained 
when cells were surface labeled with ~2~I. 
on fibronectin or laminin, produced higher levels of this pro- 
tease than the R6 clone. However, on plastic, all lines pro- 
duced similar levels. The low levels of metalloproteinases 
produced by all clones, and the apparent absence of activated 
forms of  either metalloproteinases or plasminogen activators 
are consistent with the lack of invasiveness of these cells in 
the Matrigel invasion assay. 
Tumor Formation in Nude Mice 
Finally, we evaluated the ability of our transfected 293 cell 
clones to form tumors when subcutaneously injected into 
nude mice. Because the parent 293 cells are tumorigenic in 
this  assay  and  we thus  anticipated at best  a  quantitative 
modulation of tumor formation rather than an all-or-none 
effect, we concentrated on the difference  between the clones 
presenting  the two extremes,  i.e.,  the control clones and 
clones  overproducing active  TGF-/3.  Several experiments 
using different cell numbers as inocula were used and the tu- 
mor incidence and size were measured at regular intervals 
(Table HI). As usually occurs in this type of experiment, the 
incidence of tumor formation differed among individual cell 
clones and tumor volumes differed among animals injected 
with cells from the same clone. This presumably reflects 
variability in tumor cell survival and tumor growth during 
the early stages of the experiment. Despite this heterogene- 
ity,  major  differences between  the  TGF-/3-overproducing 
clones and the control clones were evident. For example, in 
experiments using single injections of an inoculum of 6  x 
1@ cells, 9 of 12 mice injected with cells producing active 
TGF-/3  (05  and  C19)  developed subcutaneous  tumors at 
the site of injection, compared with only 2 of 12 mice in- 
jected with the control clones. The clones that secreted latent 
TGF-/3 (B6 and B9) were generally less tumorigenic than the 
C15  and C19 clones and more closely resembled the con- 
trols. This suggested that active TGF-/3 secreted in the envi- 
ronment of the injected cells may have been an important 
contributor to tumor  initiation.  We  also  injected several 
mice with cells from a  control clone at one site and cells 
overexpressing active TGF-/3 at a separate site. The overall 
incidence of tumor formation by these different cell clones 
did not differ significantly from that observed in mice receiv- 
ing one injection at a single site (Table III). 
Besides this difference in tumor incidence and presumably 
related to it, there were also differences in time of appear- 
ance.  This  was  apparent  in  two  separate  experiments  in 
which mice were injected with greater numbers of cells. For 
example, when mice were injected with 4  x  106 cells, all 
animals developed tumors at the site of injection. However, 
tumors generated from the active TGF-/3 overproducing cells 
were detected earlier and grew to large size more rapidly 
(Table IIIB). 
None  of the  tumor-beating  mice  were  found  to  have 
metastatic lesions in any of the examined tissues. Histologi- 
cally,  there  were  no  significant or  consistent differences 
among the tumors, although in one of the two experiments 
in which a histological evaluation was carried out on many 
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A. Cell clone  Incidence  Tumor volumes 
(ram  3) 
Single injection 
R1  1/6  71 
R6  1/6  24 
C15  5/6  177, 327, 349, 874, 1360 
C19  4/6  10, 46, 91, 110 
R8  2/5  149, 649 
R4  1/5  451 
B9  1/5  29 
R6  2/6  213, 1073 
B6  2/6  25, 51 
Double injection 
R1 (shoulder)  2/4  255, 2230 
C15 (flank)  4/4  475, 622, 1340, 2260 
R6 (shoulder)  0/6 
C19 (flank)  3/6  69, 73, 77 
B.  Average tumor volume 
Cram  ~; 
Cell clone  Day  17  Day 20  Day 25 
R1  5.5  (+  8)  69  (+  79)  312  (•  213) 
C19  223  (•  160)  357  (+  162)  578 (•  195) 
In A, mice received 6  x  l0  s cells in a volume of 0.2 ml subcutaneously per 
injection. Tumor measurements were made after killing the mice 4 wk later. 
In B, mice received 4  x  106 cells in 0.2 ml subcutaneously. Tumor measure- 
merits were made on the indicated days post inoculation. All mice developed 
tumors, and average tumor volumes for five mice (with SD) are provided. 
tumors,  those  derived  from  clones  overproducing active 
TGF-/~ had a more fibrotic appearance. Desmoplastic host 
response at the tumor site was variable and generally mild, 
and local invasion, when evident, was minimal. The lack of 
invasiveness and metastasis of the transfected cells in vivo, 
despite their increased tumor-forming ability, is consistent 
with their lack of invasiveness in the in vitro Matrigel assay 
and their low levels of metalloproteinase production. 
Discussion 
Several studies have shown that tumor cells display increased 
synthesis of TGF-/3 in comparison to their normal counter- 
parts, suggesting that secreting higher levels of TGF-/3 may 
advantage tumor cells in some way. These observations led 
us to evaluate the physiological consequences of increased 
expression of TGF-~ in tumor cells. However, such studies 
are greatly complicated by the diversity of biological activi- 
ties that the different forms of TGF-/3 display.  This complex- 
ity is particularly apparent when it comes to the effects of en- 
dogenous  TGF-/3  synthesis  on  neoplastic  transformation, 
tumor growth and metastatic spread. For example, it is pos- 
sible that the antiproliferative effects of TGF-~ on some tu- 
mor cells in vitro are counteracted in vivo by its potent im- 
munosuppressive effect and/or by its  induction of growth 
factor production by the surrounding host cells.  To avoid 
some of these pitfalls, we chose for our study the tumor cell 
line 293 which is known to express a functional E1A gene 
product and is therefore expected not to be affected in its 
proliferation by TGF4/. Accordingly, transfected cells over- 
expressing TGF-/3 did not display an altered proliferation 
rate. This allowed us to rule out proliferation-related physio- 
logical changes and examine potential changes that might 
otherwise have been obscured by an altered proliferation 
rate. In addition, by developing clones of this cell line that 
expressed either latent or active TGF-~I, we addressed the 
issue of whether the frequently observed increased expres- 
sion of latent, and thus "biologically inactive",  TGF-/3 by tu- 
mor  cells  has  any  physiological  relevance,  and,  if  so, 
whether these effects differ from those resulting from in- 
creased expression of active TGF-~. We evaluated the effects 
of  increased endogenous TGF-~ synthesis on the metabolism 
and adhesive properties of these tumor cells in vitro and on 
tumor formation in vivo. 
The first important finding emerging from this study is that 
overproducers of both latent or active TGF-/3 behaved simi- 
larly in the in vitro assays performed. This leads us to con- 
clude that the 293 cells overproducing latent TGF-/3 either 
directly secrete low levels of active TGF-~/or have the ability 
to convert the secreted latent form into active TGF-B which 
then induces physiological changes in an autocrine way. In 
our experiments,  the resulting low levels of TGF-/~ were 
sufficient to elicit a phenotype in vitro similar to that of cells 
overproducing active TGF-~/. Previous studies have shown 
that latent TGF-~/complex can be activated by acid treatment 
and by exposure to glycosidases and proteases, such as plas- 
min and cathepsin (Lyons et al.,  1988). Proteolytic activa- 
tion is probably the most common mechanism and is respon- 
sible for activation of TGF-# in co-cultures of endothelial 
cells and  smooth muscle cells  (Sato et al.,  1990).  Since 
many tumor cells, including 293 cells, secrete proteases such 
as plasminogen activators and cathepsins,  it is likely that 
these cells also have the ability to activate latent TGF-~/. 
Thus, our results imply that even when they secrete most or 
all TGF-j3 in its latent form, tumor cells may still undergo 
autocrine,  TGF-/3-induced physiological alterations.  It  is 
then possible that the TGF-/3 activation process may occur 
in  a  cell-associated manner,  as has been observed in co- 
cultures between endothelial and smooth muscle cells (Sato 
et al.,  1991; Dennis and Rifkin,  1991). 
In comparison with their parental controls, cells overex- 
pressing latent or active TGF-/3 underwent several changes 
in their metabolic and adhesive properties in vitro. One ma- 
jor change was their increased anaerobic metabolism. It has 
long been known that tumor cells have an increased rate of 
glycolysis and our results suggest that increased TGF-/3 syn- 
thesis, or its activation, by the tumor cells may contribute 
significantly to this alteration in cellular metabolism. Since 
the transfected 293 cells did not proliferate more rapidly, 
presumably as a result of the functional E1A gene product 
(Pietenpol et al., 1990), our results indicate both that the in- 
creased glycolysis is independent from the proliferation rate 
and that the TGF-/3-induced cellular signalling mechanisms 
that regulate glycolysis and proliferation are distinct. 
The other major phenotypic change observed in TGF-/3- 
overproducing cells was increased substratum adhesiveness. 
The  neomycin-resistant control  clones,  like  the  untrans- 
fected parental cell line, were unable to adhere to plastic in 
the  absence of serum.  Instead,  they proliferated in  non- 
adherent clumps. In contrast, cells overexpressing latent or 
active TGF-/3 adhered to the plastic, spread and proliferated 
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of our in vivo results, was the observation that only the C15 
and C19 clones overproducing active TGF-/3, and not those 
overproducing latent TGF-/3, adhered and survived at low 
cell inoculum. In parallel experiments using different culture 
conditions,  the control  cell  line R6 was unable  to attach 
rapidly or to spread on laminin when cultured in serum-free 
medium in the presence of Nutridoma, whereas the TGF-~ 
overproducing clones 136 and C15 attached readily and spread 
on laminin. Thus, at least under these conditions, expression 
of TGF-j3 strongly influenced the ability of 293 cells to ad- 
here to the substratum. Such differences in adhesive proper- 
ties could be of importance in vivo in regulating the ability 
of small numbers of cells to initiate tumor formation. 
Consistent with the changes in adhesive behavior were the 
enhanced levels of expression of fibronectin mRNA and of 
several E1 integrin complexes. This observation is consistent 
with a large body of information documenting the ability of 
TGF-B to enhance  extracellular  matrix production  (Mas- 
sagu6 et al.,  1990; Bamard et al.,  1990). Production of a 
broad range of integrins was increased in the B6 as well as 
the C15 clones overproducing TGF-/3. This may favor oppor- 
tunistic adhesive behavior which could enhance survival in 
vivo. The observed increased expression of  o~ 3/~, a promis- 
cuous receptor that recognizes laminin, collagen, and fibro- 
nectin, may be of particular  importance,  as it has been re- 
ported that enhanced expression of a 3/~ or elevated ratios 
of c~ 3//51 to ~x5//31 accompany oncogenic transformation in 
several cell lines (Plantefaber and Hynes, 1989). Taken  to- 
gether these data support the idea that acquisition of an op- 
timal adhesion phenotype is permissive for a more rapid and 
successful colonization by tumor cells of  their immediate en- 
vironment. 
Having stably transfected clones that produced increased 
amounts of TGF-/5 gave us the unique opportunity to deter- 
mine the consequences of  TGF-t3 overexpression in vivo, be- 
cause local concentration gradients of  tumor-derived factors 
and their effect on nearby host cells could be reproduced. 
Two published  studies have used stable  clone  transfected 
with the TGF-~I eDNA and have demonstrated significant in 
vivo suppression of  cytolytic  T cell and natural killer cell ac- 
tivities (Torre-Amione et al., 1990; Wallick et al., 1990). In 
the present study, we found that at a low tumor cell inocu- 
lure,  293  cells that overexpressed active TGF-/3 produced 
subcutaneous  tumors more readily than control 293  cells. 
This may reflect some degree of immunosuppression  or a 
growth advantage for these cells when few in number. This 
increase in tumorigenicity may also be related to our obser- 
vation that only the clones overexpressing active TGF-/3 sur- 
vived when plated in serum-free medium at very low density. 
In addition,  the increased  ability  of cells  overexpressing 
TGF-/3 to produce  and interact  with extraceilular  matrix 
could create a more permissive environment for tumor cell 
proliferation and tumor formation.  This explanation would 
be consistent with recent results, documenting an increase 
in tumor formation when tumor cells were injected together 
with the basement membrane analog Matrigel (Fridman et 
al., I99I). The ~eater incidence of tumor formation with 
the C15 and C19 clones was apparently not the result of  a sys- 
temic effect from the secreted TGF-/3 since tumor formation 
from control clones injected into the same animals was not 
increased.  Although enhanced production of TGF-/5 by 293 
cells may generate a particular  adhesion phenotype that is 
favorable for their anchorage and permissive for their sur- 
vival  in vivo,  such an adhesion  phenotype  is clearly not 
sufficient for successful tumor initiation.  Only the clones 
producing active TGF-/3 had enhanced rates of  tumor forma- 
tion when injected into nude mice at low inoculum levels, 
suggesting that the active TGF43 may have profound effects 
on the imme~ate environment of the tumor cells, e.g., by 
inducing  enhanced  matrix  formation  or  growth  factor 
production by the neighboring ceils, or increased prolifera- 
tion by host fibroblasts. In this context it is important to note 
that histological evaluation of some, but not all, tumors de- 
rived from cells  overproducing  active TGF-/3 showed in- 
creased matrix formation and interstitial fibroblast prolifera- 
tion in comparison  with tumors  derived  from the control 
clones. Neither the parental cell line, nor any of the TGF-/~- 
overexpressing clones were metastatic in this animal model. 
Consistent  with these observations,  the transfected clones 
did not produce higher levels of metalloproteinases and did 
not display activated forms of metaUoproteinases or plas- 
minogen activators. 
The observed increased tumorigenicity by 293 cells over- 
expressing active TGF-/3 is not necessarily inconsistent with 
some recent results indicating that a colon carcinoma cell 
line transfected with an antisense mRNA expression vector 
for TGF-131 caused a higher tumor incidence in nude mice 
(Wu et al., 1992) or that a rat prostate cell line transfected 
with a  latent  TGF-B expression  vector demonstrated  en- 
hanced tumor growth (Steiner and Barrack,  1992). These re- 
cent studies were performed in cell lines that were sensitive 
to the growth-regulatory effects of  TGF-t3, whereas we inten- 
tionally focused on a tumor cell line which is insensitive to 
the direct growth modulatory activities of TGF-/3 and have 
evaluated the tumorigenicity of clones with similar rates of 
proliferation, thus allowing a more direct evaluation of, e.g., 
the physiological consequences of alterations in cell-matrix 
interactions. It is thus possible that the inhibitory effects of 
TGF-13 on cell proliferation could counteract altered adhe- 
sive interactions of the cells with the environment in deter- 
mining tumor cell proliferation in vivo. Thus, the advantage 
of an increased endogenous TGF-# synthesis for tumorige- 
nicity may depend on the balance of these two parameters, 
and on the degree of local TGF-15-induced  immunosuppres- 
sion, and thus may vary depending on the tumor type or cell 
line. On the other hand, it is also important to realize that 
many tumor cells have lost their sensitivity to the growth in- 
hibitory activities of  TGF-#, as is the case with the 293 cells, 
possibly as a consequence of functional inactivation of the 
Rb gene product (Pietenpol et al., 1990) and possibly also 
as a step in the progression of tumor cells of full malignancy 
(Wakefield and Sporn,  1990). 
In conclusion,  we have evaluated the role of endogenous 
TGF43 overexpression on several physiological parameters 
of tumor cells and tumor formation, using an E1A trans- 
formed tumor cell line. We found that cells overexpressing 
latent or active TGF-tS, compared with control transfected 
cells, displayed similar physiological changes in vitro with- 
out a change in proliferation rate. The major effects of the 
increased TGF-~ synthesis, evaluated in this study, were in- 
creased glycolysis and enhanced cell-matrix adhesiveness. 
In addition,  increased release  of active TGF43 resulted in 
higher incidence of tumor formation.  These findings may 
The Journal  of Cell Biology,  Volume 118,  1992  724 have  relevance  to  pathological  tumor  formation  since,  at 
least in several systems, it has been documented that tumor 
cells release higher levels of TGF-/3 compared to their non- 
malignant controls. In addition, several tumor cell lines have 
been shown to release significant levels of already activated 
TGF-fl (Knabbe et al., 1987; Schwarz et al., 1990; Constam 
et al.,  1992). The cell line used in our study was minimally 
invasive and non-metastatic. As such, it does not provide an 
adequate assessment of the potential role of TGF-fl in tumor 
cell  metastatic  behavior.  Similar experiments  with meta- 
static tumor cell lines are in progress to address this issue. 
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